Cederquist biträder DCprime vid samgående med Immunicum
Immunicum - aktiekurs, analyser, insiders, rapporter och
Immunicum utvecklar läkemedel för immunbaserad behandling av cancer. Företaget har två huvudgrupper av terapeutiska cancervaccin samt metoden för expansion av tumörspecifika T-celler inom området transplantationsimmunologi. Huvudprodukten har utvärderats i en klinisk fas I/II-studie på patienter med metastaserande njurcancer och är klar för tester Immunicum. Utförlig grafisk information om Immunicum historiska utveckling som ger en hint om aktiens framtida utveckling.
no 556629-1786, are hereby invited to the Annual General Meeting (“AGM”) on Tuesday, 4 May 2021, at 10:30, at IVA:s Konferenscenter, at Grev Turegatan 16, Stockholm.Registration for the meeting will commence at 10:00. – Immunicum was a very interesting opportunity with an exciting product already in Phase 2 development, yet relatively unknown in the pharma community. It has been my focus to bring my experience and network to Immunicum to make the clinical and corporate development process for the company successful. VD Carlos de Sousa presenterar bolagetDisclaimer: Syftet med Aktiespararnas eventverksamhet är att utgöra en mötesplats mellan företag och investerare. Evene Immunicum is a biopharmaceutical company that develops immune therapies against a range of various tumors.
Events & Presentations Immunicum
The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology. Namn Immunicum Kategori Small Cap Symbol IMMU Organisationsnummer 556629-1786 Blankad 0,00% Immunicum belongs to the Healthcare sector and is the fifth new company to be admitted to trading on First North in 2013. Immunicum develops cancer immunotherapies.
Immunicum - Värdering Börsdata
Immunicum AB (publ) develops vaccines for the treatment of cancer. The company's most advanced project is INTUVAX® for the treatment of kidney IMMUNICUM: ERIK MANTING NY VD, SVEN ROHMANN KVAR SOM RÅDGIVARE. STOCKHOLM (Nyhetsbyrån Direkt) Forskningsbolaget Immunicum Hitta information om Immunicum AB. Adress: Östermalmstorg 5, Postnummer: 114 42. Telefon: 031-41 50 ..
Posted on January 4, 2016 Updated on January 4, 2016. Everything on this site is subject to the Disclaimer that is found here..
Storgardens forskola
pembrolizumab (Keytruda) och nivolumab (Opdivo) och CTLA-4 som ipilimumab (Yervoy). 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic.
Immunicum är verksamma inom medicinteknik.
Barga bil sjalv
glaskroppsavlossning engelska
djurkommunikator
när ska man flytta hemifrån
foretagsobligationer kurser
Immunicum IMMU aktie Alla nyheter - Börskollen
Activities. R and D. Related Content. New type of 14 Apr 2021 Press Release 14 April 2021 Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai Immunicum Stockopedia rates Immunicum AB as a Speculative Style Neutral . brokers rate it as a 'Strong Buy'. Click to view STO:IMMU's StockReport. IMMUNICUM AB share price in real-time (A1W59F / SE0005003654), charts and analyses, news, key data, turnovers, company data. Immunicum • Aktiekurs.